↓ Skip to main content

Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature

Overview of attention for article published in European Journal of Pediatrics, November 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 X users

Citations

dimensions_citation
50 Dimensions

Readers on

mendeley
153 Mendeley
Title
Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature
Published in
European Journal of Pediatrics, November 2015
DOI 10.1007/s00431-015-2670-x
Pubmed ID
Authors

O. Bonnot, D. Cohen, D. Thuilleaux, A. Consoli, S. Cabal, M. Tauber

Abstract

Prader-Willi syndrome (PWS) is a rare genetic syndrome. The phenotype includes moderate to intellectual disability, dysmorphia, obesity, and behavioral disturbances (e.g., hetero and self-injurious behaviors, hyperphagia, psychosis). Psychotropic medications are widely prescribed in PWS for symptomatic control. We conducted a systematic review of published literature to examine psychotropic medications used in PWS. MEDLINE was searched to identify articles published between January 1967 and December 2014 using key words related to pharmacological treatments and PWS. Articles with original data were included based on a standardized four-step selection process. The identification of studies led to 241 records. All selected articles were evaluated for case descriptions (PWS and behavioral signs) and treatment (type, titration, efficiency, and side effects). Overall, 102 patients were included in these studies. Treatment involved risperidone (three reports, n = 11 patients), fluoxetine (five/n = 6), naltrexone (two/n = 2), topiramate (two/n = 16), fluvoxamine (one/n = 1), mazindol (one/n = 2), N-acetyl cysteine (one/n = 35), rimonabant (one/n = 15), and fenfluramine (one/n = 15). We identified promising treatment effects with topiramate for self-injury and impulsive/aggressive behaviors, risperidone for psychotic symptoms associated with uniparental disomy (UPD), and N-acetyl cysteine for skin picking. The pharmacological approach of behavioral impairment in PWS has been poorly investigated to date. Further randomized controlled studies are warranted. What is Known: • Behavioral disturbances in Prader-Willi syndrome including aggressive reactions, skin picking, and hyperphagia might be very difficult to manage. • Antipsychotic drugs are widely prescribed, but weight gain and increased appetite are their major side effects. What is New: • Topiramate might be efficient for self-injury and impulsive/aggressive behaviors, N-acetyl cysteine is apromising treatment for skin picking and Antidepressants are indicated for OCD symptoms. • Risperidone is indicated in case of psychotic symptoms mainly associated with uniparental disomy.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 153 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Indonesia 1 <1%
Germany 1 <1%
Unknown 151 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 16 10%
Student > Master 14 9%
Researcher 13 8%
Student > Doctoral Student 13 8%
Student > Ph. D. Student 11 7%
Other 33 22%
Unknown 53 35%
Readers by discipline Count As %
Medicine and Dentistry 35 23%
Psychology 19 12%
Nursing and Health Professions 8 5%
Agricultural and Biological Sciences 8 5%
Biochemistry, Genetics and Molecular Biology 6 4%
Other 21 14%
Unknown 56 37%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 June 2016.
All research outputs
#16,040,357
of 25,371,292 outputs
Outputs from European Journal of Pediatrics
#2,937
of 4,358 outputs
Outputs of similar age
#216,739
of 399,797 outputs
Outputs of similar age from European Journal of Pediatrics
#25
of 42 outputs
Altmetric has tracked 25,371,292 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,358 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 399,797 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.